Research article Open Access
Like 0


The lack of an anti-capsular vaccine against serogroup B meningococcal disease has necessitated the exploration of alternative vaccine candidates, mostly proteins exhibiting varying degrees of antigenic variation. Analysis of variants of antigen-encoding genes is facilitated by publicly accessible online sequence repositories, such as the PubMLST database and the associated Meningitis Research Foundation Meningococcus Genome Library (MRF-MGL). We investigated six proposed meningococcal vaccine formulations by deducing the prevalence of their components in the isolates represented in these repositories. Despite high diversity, a limited number of antigenic variants of each of the vaccine antigens were prevalent, with strong associations of particular variant combinations with given serogroups and genotypes. In the MRF-MGL and globally, the highest levels of identical sequences were observed with multicomponent/multivariant vaccines. Our analyses further demonstrated that certain combinations of antigen variants were prevalent over periods of decades in widely differing locations, indicating that vaccine formulations containing a judicious choice of antigen variants have potential for long-term protection across geographic regions. The data further indicated that formulations with multiple variants would be especially relevant at times of low disease incidence, as relative diversity was higher. Continued surveillance is required to monitor the changing prevalence of these vaccine antigens.


Article metrics loading...

Loading full text...

Full text loading...



  1. Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;322(8346):355-7.  https://doi.org/10.1016/S0140-6736(83)90340-9  PMID: 6135869 
  2. Bjune G, Høiby EA, Grønnesby JK, Arnesen O, Fredriksen JH, Halstensen A, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338(8775):1093-6.  https://doi.org/10.1016/0140-6736(91)91961-S  PMID: 1682541 
  3. O’Hallahan J, Lennon D, Oster P. The strategy to control New Zealand’s epidemic of group B meningococcal disease. Pediatr Infect Dis J. 2004;23(12) Suppl;S293-8. PMID: 15597072 
  4. Sierra GVG, Campa CH, Garcia LI, Sotolongo FP, Izquierdo LP, Valcarcel MN, et al. Efficacy evaluation of the Cuban vaccine VA-MENGOC-BC against disease caused by serogroup B Neisseria meningitidis. In: Achtman Mea, editor. Niesseria 1990. Berlin: Walter de Gruyter; 1991. p. 129-134.
  5. European Centre for Disease Prevention and Control (ECDC). Annual epidemiological report 2013. Reporting on 2011 surveillance data and 2012 epidemic intelligence data. Stockholm: ECDC; 2013. Available from: http://ecdc.europa.eu/en/publications/Publications/annual-epidemiological-report-2013.pdf
  6. Castelblanco RL, Lee M, Hasbun R. Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis. 2014;14(9):813-9.  https://doi.org/10.1016/S1473-3099(14)70805-9  PMID: 25104307 
  7. Kaaijk P, van Straaten I, van de Waterbeemd B, Boot EP, Levels LM, van Dijken HH, et al. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine. 2013;31(7):1065-71.  https://doi.org/10.1016/j.vaccine.2012.12.031  PMID: 23273968 
  8. Bambini S, Piet J, Muzzi A, Keijzers W, Comandi S, De Tora L, et al. An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands. PLoS ONE. 2013;8(5):e65043.  https://doi.org/10.1371/journal.pone.0065043  PMID: 23717687 
  9. Nissen MD, Marshall HS, Richmond PC, Jiang Q, Harris SL, Jones TR, et al. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J. 2013;32(4):364-71.  https://doi.org/10.1097/INF.0b013e31827b0d24  PMID: 23114369 
  10. Brehony C, Jolley KA, Maiden MC. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev. 2007;31(1):15-26.  https://doi.org/10.1111/j.1574-6976.2006.00056.x  PMID: 17168997 
  11. Jolley KA, Brehony C, Maiden MC. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev. 2007;31(1):89-96.  https://doi.org/10.1111/j.1574-6976.2006.00057.x  PMID: 17168996 
  12. Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, Brehony C, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev. 2007;31(1):27-36.  https://doi.org/10.1111/j.1574-6976.2006.00060.x  PMID: 17168995 
  13. Brehony C, Wilson DJ, Maiden MC. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology. 2009;155(Pt 12):4155-69.  https://doi.org/10.1099/mic.0.027995-0  PMID: 19729409 
  14. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72(4):2088-100.  https://doi.org/10.1128/IAI.72.4.2088-2100.2004  PMID: 15039331 
  15. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003;197(6):789-99.  https://doi.org/10.1084/jem.20021911  PMID: 12642606 
  16. O’Hallahan J, Lennon D, Oster P, Lane R, Reid S, Mulholland K, et al. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine. 2005;23(17-18):2197-201.  https://doi.org/10.1016/j.vaccine.2005.01.061  PMID: 15755594 
  17. Bjune G, Grønnesby JK, Høiby EA, Closs O, Nøkleby H. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann. 1991;14(2):125-30, discussion 130-2. PMID: 1812425 
  18. Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19(4):566-73.  https://doi.org/10.3201/eid1904.111799  PMID: 23628376 
  19. Hunter PR, Gaston MA. Numerical index of the discriminatory ability of typing systems: an application of Simpson’s index of diversity. J Clin Microbiol. 1988;26(11):2465-6. PMID: 3069867 
  20. Grundmann H, Hori S, Tanner G. Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms. J Clin Microbiol. 2001;39(11):4190-2.  https://doi.org/10.1128/JCM.39.11.4190-4192.2001  PMID: 11682558 
  21. Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science. 2000;287(5459):1809-15.  https://doi.org/10.1126/science.287.5459.1809  PMID: 10710307 
  22. Brunelli B, Del Tordello E, Palumbo E, Biolchi A, Bambini S, Comanducci M, et al. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine. 2011;29(5):1072-81.  https://doi.org/10.1016/j.vaccine.2010.11.064  PMID: 21130753 
  23. Comanducci M, Bambini S, Caugant DA, Mora M, Brunelli B, Capecchi B, et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun. 2004;72(7):4217-23.  https://doi.org/10.1128/IAI.72.7.4217-4223.2004  PMID: 15213166 
  24. Reuter S, Ellington MJ, Cartwright EJ, Köser CU, Török ME, Gouliouris T, et al. Rapid bacterial whole-genome sequencing to enhance diagnostic and public health microbiology. JAMA Intern Med. 2013;173(15):1397-404.  https://doi.org/10.1001/jamainternmed.2013.7734  PMID: 23857503 
  25. Roetzer A, Diel R, Kohl TA, Rückert C, Nübel U, Blom J, et al. Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study. PLoS Med. 2013;10(2):e1001387.  https://doi.org/10.1371/journal.pmed.1001387  PMID: 23424287 
  26. Price JR, Didelot X, Crook DW, Llewelyn MJ, Paul J. Whole genome sequencing in the prevention and control of Staphylococcus aureus infection. J Hosp Infect. 2013;83(1):14-21.  https://doi.org/10.1016/j.jhin.2012.10.003  PMID: 23164609 
  27. Croucher NJ, Finkelstein JA, Pelton SI, Mitchell PK, Lee GM, Parkhill J, et al. Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet. 2013;45(6):656-63.  https://doi.org/10.1038/ng.2625  PMID: 23644493 
  28. Jolley KA, Maiden MC. Automated extraction of typing information for bacterial pathogens from whole genome sequence data: Neisseria meningitidis as an exemplar. Euro Surveill. 2013;18(4):20379. PMID: 23369391 
  29. Bratcher HB, Bennett JS, Maiden MCJ. Evolutionary and genomic insights into meningococcal biology. Future Microbiol. 2012;7(7):873-85.  https://doi.org/10.2217/fmb.12.62  PMID: 22827308 
  30. van der Ley P, van der Biezen J, Poolman JT. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine. 1995;13(4):401-7.  https://doi.org/10.1016/0264-410X(95)98264-B  PMID: 7793138 
  31. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000;3(5):445-50.  https://doi.org/10.1016/S1369-5274(00)00119-3  PMID: 11050440 
  32. Watkins ER, Maiden MC. Persistence of hyperinvasive meningococcal strain types during global spread as recorded in the PubMLST database. PLoS ONE. 2012;7(9):e45349.  https://doi.org/10.1371/journal.pone.0045349  PMID: 23028953 
  33. Russell JE, Urwin R, Gray SJ, Fox AJ, Feavers IM, Maiden MC. Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines. Microbiology. 2008;154(Pt 4):1170-7.  https://doi.org/10.1099/mic.0.2007/014761-0  PMID: 18375809 
  34. Law DKS, Zhou J, Deng S, Hoang L, Tyrrell G, Horsman G, et al. Determination of serotyping antigens, clonal analysis and genetic characterization of the 4CMenB vaccine antigen genes in invasive Neisseria meningitidis from Western Canada, 2009 to 2013. J Med Microbiol. 2014;63(Pt 11):1490-9.  https://doi.org/10.1099/jmm.0.079921-0  PMID: 25165123 
  35. Holst J, Comanducci M, Bambini S, Muzzi A, Comandi S, Oksnes J, et al. Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway. Vaccine. 2014;32(23):2722-31.  https://doi.org/10.1016/j.vaccine.2014.02.068  PMID: 24631075 
  36. Brehony C, Trotter CL, Ramsay ME, Chandra M, Jolley KA, van der Ende A, et al. Implications of differential age distribution of disease-associated meningococcal lineages for vaccine development. Clin Vaccine Immunol. 2014;21(6):847-53.  https://doi.org/10.1128/CVI.00133-14  PMID: 24695776 
  37. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107(45):19490-5.  https://doi.org/10.1073/pnas.1013758107  PMID: 20962280 
  38. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13(5):416-25.  https://doi.org/10.1016/S1473-3099(13)70006-9  PMID: 23414709 
  39. Tzanakaki G, Hong E, Kesanopoulos K, Xirogianni A, Bambini S, Orlandi L, et al. Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol. 2014;14(1):111.  https://doi.org/10.1186/1471-2180-14-111  PMID: 24779381 

Data & Media loading...

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error